Metabolism of docetaxel by human cytochromes P450: Interactions with paclitaxel and other antineoplastic drugs

Cancer Research

Volumn 56, Issue 1, 1996, Pages 58-65

  Royer, Isabelle ^a   Monsarrat, Bernard ^a   Sonnier, Michelle ^b   Wright, Michel ^a   Cresteil, Thierry ^b  

^a Lab Pharmacologie/Toxicologie F   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CISPLATIN; CYTOCHROME P450; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; HEXOBARBITAL; KETOCONAZOLE; MEPHENYTOIN; MIDAZOLAM; ORPHENADRINE; PACLITAXEL; QUINIDINE; RANITIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TESTOSTERONE; TOLBUTAMIDE; TROLEANDOMYCIN; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG RETENTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; ISOENZYMES; LIVER; MICROSOMES, LIVER; PACLITAXEL; PREGNANCY; TAXOIDS;

EID: 0030051928     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Schiff, P B., and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblasts cells. Proc. Natl. Acad Sci. USA, 77: 1561-1565, 1980.
2. Ringel, I , and Horwitz, S. B Studies with RP 56976 (Taxotere) a semisynthetic analogue of Taxol. J. Natl. Cancer Inst., 83: 288-291, 1991.
3. Bissery, M C , Guénard, D., Guéritte-Voegelein, F , and Lavelle, F Experimental antitumor activity of Taxotere (RP 56976. NSC 628503): a Taxol analogue Cancer Res., 51: 4845-4852, 1991.
4. ® and Taxotere on primary cultures and established cell lines of human ovarian cancer. Stem Cells, 11: 528-535, 1993.
5. ®) and cisplatin against human tumour and normal bone marrow cells. Anticancer Res , 14: 205-208, 1994.
6. Woo, D. D. L , Miao, S. Y. P., Pelayo, J. C., and Woolf, A. S Taxol inhibits progression of congenital polycystic kidney disease Nature (Lond.), 368: 750-753, 1994
7. Hill, B. T., Whelan, R. D. H , Shellard, S A., McClean, S., and Hosking, L. K. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest. New Drugs, 12: 169-182, 1994.
8. Trimble, E. L., Adams, J D , Vena, D., Hawkins, M. J., Friedman, M. A , Fisherman, J. S., Christian, M. C., Canetta, R., Onetto, N., Hayn, R., and Arbuck, S G. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute treatment referral center 9103. J Clin. Oncol., 11: 2405-2410, 1993
9. Chevallier, B , Fumoleau, P , Kerbrat, P , Dieras, V., Roche, H., Krakowski, I., Azli, N , Bayssas, M., Lentz, M A , and Van Glabbeke, M. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the clinical screening cooperative group of the European organization for research and treatment of cancer. J. Clin. Oncol , 13: 314-322, 1995.
10. Francis, P. A., Rigas, J. R., Kris, M. G., Pisters, K. M. W , Orazem, J P , Woolley, K J., and Heelan, R. T Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer J. Clin. Oncol., 12: 1232-1237, 1994.
11. ®), a review of preclinical and clinical experience. 2. Clinical experience. Anticancer Drugs, 6: 356-368, 1995.
12. Rowinsky, E. K., Ross, C., and Donehower, M. D Paclitaxel N. Engl. J. Med., 332: 1004-1014, 1995.
13. Want, M. C., Taylor, H. L., Wall, M. E , Coggon, P., and McPhail, A. T Plant antitumor agents. VI: The isolation and structure of taxol, a novel antileukemic and antitumor agent from Toxus brevifolia. J. Am. Chem. Soc , 93: 2325-2327, 1971.
14. Colin, M , Guénard, D., Guéritte-Voegelin, F., and Potier, P. Process for preparing derivatives of baccatin III and 10-deacetyl baccatin III. Eur. Patent Application. EP 253,738 01/20/88, U. S patent 4924012, granted May 8, 1990.
15. Guéritte-Voegelin, F., Guénard, D., Lavelle, F , Le Goff, M. T., Mangatal, L., and Potier, P. Relationships between the structure of Taxol analogues and their antimitotic activity. J. Med. Chem., 34: 992-998, 1991.
16. Monsarrat, B., Mariel, E., Cros, S., Garès, M., Guénard, D , Guéritte-Voegelin, F., and Wright, M. Taxol metabolism: isolation and identification of three major metabolites of taxol in rat bile. Drug Metab Dispos., 18: 895-901, 1990.
17. Monsarrat, B., Alvinerie, P., Wright, M., Dubois, J., Guéritte-Voegelein, F , Guénard, D , Donehower, R , and Rowinsky, E. Hepatic metabolism and biliary clearance of Taxol in rats and human. J. Natl. Cancer Inst. Monogr., 15: 39-46, 1993.
18. Harris, J. W., Katki, A., Anderson, L. W , Churny, G. N., Paukstelis, J. V., and Collins, J M. Isolation, structural determination and biological activity of 6α-hydroxytaxol. The principal human metabolite of Taxol. J. Med. Chem , 37: 706-709, 1994.
19. Cresteil, T., Monsarrat, B., Alvinerie, P., Tréluyer, J. M., Vieira, I., and Wright, M. Taxol metabolism by human liver microsomes, identification of cytochrome P450 isozymes involved in its biotransformation Cancer Res., 54: 386-92, 1994.
20. Kumar, G. N., Walle, U. K., and Walle, T. Cytochrome P450 3A-mediated human liver microsomal taxol 6α-hydroxylation. J. Pharmacol. Exp. Ther., 268: 1160-1165, 1994.
21. Harris, J W., Rahman, A., Kim, B. R., Guengerich, F P , and Collins, J M Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res., 54: 4026-4035, 1994.
22. Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalez, F. J., and Harris, J. W. Selective biotransformation of Taxol to 6α-hydroxytaxol by human cytochrome P450 2C8 Cancer Res., 54: 5543-5546, 1994.
23. ®). Tetrahedron Lett., 35 3715-3718, 1994
24. Gaillard, C., Monsarrat, B., Vuilhorgne, M., Royer, I., Monegier, B., Sabé, S , Guénard, D., Gires, P., Archimbaud, Y., Wright, M., and Sanderink, G J. Docetaxel (Taxotère). Metabolism in the rat Proc Am. Assoc. Cancer Res., 35: 428, 1994
25. ® (docetaxel) Cancer Surv., 17: 305-313, 1993.
26. Kroemer, H K., Echizen, H., Heidemann, H., and Eichelbaum, M. Predictability of the in vivo metabolism of verapamil from in vitro data, contribution of individual metabolic pathways and stereoselective aspects. J. Pharmacol. Exp. Ther., 260 1052-1057, 1992.
27. Zhou-Pan, X. R., Sérée, E., Zhou, X. J., Placidi, M , Maurel, P., Barra, Y., and Rhamani, R. Involvement of human liver cytochrome P450 3A in vinblastine metabolism, drug interactions. Cancer Res., 53: 5121-5126, 1993
28. Jacolot, F , Simon, I., Dreano, Y., Beaune, P., Riche, C , and Berthou, F Identification of the cytochrome P450 3A family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol , 41: 1911-1919, 1991.
29. Cresteil, T., Flinois, J. P., Pfister, A., and Leroux, J. P. Effect of microsomal preparations and induction on cytochrome P450-dependent monooxygenases in fetal and neonatal rat liver Biochem Pharmacol., 28: 2057-2063, 1979.
30. Greun, H. Synthesesteigerung und abbauhemmung bei der vermchrung der mikrosomalen cytochrome P450 und b5 durch phenobarbital. Arch. Pharmacol., 266: 261-275, 1970.
31. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R J. Protein measurement with the Folin reagent. J. Biol. Chem., 193: 265-275, 1951.
32. Burke, M D., Thompson, S., Elcombe, C. R., Halpert, J , Haaparanta, T , and Mayer, R. T. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P450 Biochem Pharmacol , 34: 3337-3345, 1985.
33. Chung, L. W. K., and Chao, H. Neonatal imprinting and hepatic cytochrome P450. Comparison of testosterone hydroxylation in a reconstituted system between neonatally imprinted and nonimprinted rats Mol Pharmacol , 18: 543-549, 1980.
34. Knodell, R G., Hall, S. D., Wilkinson, G. R., and Guengerich, F. P. Hepatic metabolism of tolbutamide, characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol. Exp. Ther , 241: 1112-1119, 1987.
35. Reilly, P. E. B., Thompson, D. A , Mason, S. R., and Hooper, W. Cytochrome P450IIIA enzymes in rat liver microsomes. Involvement in C3-hydroxylation of diazepam and nordazepam but not N-dealkylation of diazepam and temazepam. Mol. Pharmacol., 37: 767-774, 1990.
36. Royer, I., Alvinerie, P , Ho, L K., Wright, M., and Monsarrat, B. Paclitaxel metabolites in human plasma and urine identification of 6α-hydroxytaxol, 7-epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry. Rapid Commun. Mass Spectrom, 9: 495-502, 1995
37. Wright, M., Monsarrat, B , Royer, I., Rowinsky, E. K., Donehower, R. C., Cresteil, T., and Guénard, D. Metabolism and pharmacology of taxoids In: V. Farina (ed.), Chemistry and Pharmacology of Taxol and Its Denvatives, pp 131-164. New York: Elsevier, 1995.
38. Cresteil, T., Beaune, P., Kremers, P., Celier, C., Guengerich, F. P., and Leroux, J P Immunoquantification of epoxide hydrolase and cytochrome P-450 isoenzymes in fetal and adult human liver microsomes. Eur J Biochem., 151: 345-350, 1985.
39. Komori, M , Nishio, K., Kitada, M., Shiramatsu, K., Muroya, K., Soma, M., Nagashima, K., and Kamataki, T. Fetus-specific expression of a form of cytochrome P450 in human livers. Biochemistry, 29: 4430-4433, 1990.
40. Schuetz, J. D., Beach, D. L., and Guzelian, P. S. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics, 4: 11-20, 1994
41. Muller, C., Goubin, F., Ferrandis, E., Cornil-Schawrtz, I., Bailly, J. D., Bordier, C , Bénard, J., Sikic, B. I., and Laurent, G. Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells Mol. Pharmacol , 47: 51-56, 1995.
42. Muller, C., Bailly, J. D , Goubin, F , Laredo, J., Jaffrezou, J. P., Bordier, C., and Laurent, G Verapamil decreases P-glycoprotein expression in multidrug resistant human leukemic cell lines. Int J Cancer, 56: 749-754, 1994
43. Rowinski, E. K., Gilbert, M. R., McGuire, W P., Noe, D. A., Grochow, L. B., Forastiere, A. A , Ettinger, D. S., Lubejko, B. G., Satorius, S. E , Cornblath, C. B , Hendricks, C. B., and Donehower, R. C. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin. Oncol., 9: 1692-1703, 1991.
44. Klotz, U , Arvela, P., Pasanen, M , Kroemer, H , and Pelkonen, O. Comparative effects of H2-receptor antagonists on drug metabolism in vitro and in vivo. Pharmacol. Ther , 3: 157-161, 1987.
45. Knodell, R. G., Browne, D G , Gwozdz, G. P , Brian, W. R., and Guengerich, F. P. Differential inhibition of individual human liver cytochromes P450 by cimetidine. Gastroenterology, 101: 1680-1691, 1991.
46. Klecker, R. W., Jamis-Dow, C. A., Egorin, M J., Erkmen, K., Parker, R. J., Stevens, R., and Collins, J M. Effect of cimetidine, probenecid and ketoconazole on the distribution. Biliary secretion and metabolism of [3H] Taxol in the Sprague-Dawley rat. Drug Metab. Dispos., 22: 254-258, 1994.
47. Lewis, A. D., Lau, D H. M., Duran, G. E., Wolf, C. R., and Sikic, B. I. Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorabicin by human liver microsomes Cancer Res., 52: 4379-4384, 1992.